Oral Fampridine-SR Multiple Sclerosis Patients MS-F204

ID Number 07-0814

Principal Investigator(s)
Fred Lublin

Department(s) or Division(s)


The objective of this study (MS-F204 EXT) is to evaluate the long-term safety, tolerability and activity of Fampridine -SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics of Elan Corporation sponsored protocol.

Contact Information
Shelly Phelps
(212) 241-3391

Recruiting Patients: No